Taeho Greg Rhee, PhD, FACE
Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
- 15Articles
- 74.3KReads
- 2018–2026Active
- 53Collaborators
- 203Citations
About
Taeho Greg Rhee, PhD, FACE, is affiliated with the Department of Psychiatry at Yale School of Medicine. Rhee has authored 15 articles from 2018 to 2026 on topics including major depressive disorder, electroconvulsive therapy, suicide, addiction, anxiety, geriatric psychiatry, and psychopharmacology. His work encompasses clinical comparisons of ketamine and esketamine treatments, analyses of electroconvulsive therapy outcomes, and investigations into psychiatric drug development and quality of life measures in psychiatric conditions. Rhee frequently collaborates with Samuel T. Wilkinson, Robert A. Rosenheck, Kyaw Sint, Peter Jongho Na, and Roger S. McIntyre.
Publications
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
January 12, 2026
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
July 7, 2025
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.